Zhou Guo-Xiong, Huang Jie-Fei, Li Zhao-Shen, Xu Guo-Ming, Liu Feng, Zhang Hong
Department of Gastroenterology, Affiliated Hospital of Nantong Medical College, Nantong 226001, Jiangsu Province, China.
World J Gastroenterol. 2004 May 1;10(9):1337-40. doi: 10.3748/wjg.v10.i9.1337.
To study the value of monitoring K-ras point mutation at codon 12 and telomerase activity in exfoliated cells obtained from pancreatic duct brushings during endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of pancreatic cancer.
Exfoliated cells obtained from pancreatic duct brushings during ERCP were examined in 27 patients: 23 with pancreatic cancers, 4 with chronic pancreatitis. K-ras point mutation was detected with the polymerase chain reaction and restriction fragment-length polymorphism (PCR-RFLP). Telomerase activity was detected by PCR and telomeric repeat amplification protocol assay (PCR-TRAP-ELISA).
The telomerase activities in 27 patients were measured in 21 exfoliated cell samples obtained from pancreatic duct brushings. D450 value of telomerase activities in pancreatic cancer and chronic pancreatitis were 0.446+/-0.27 and 0.041+/-0.0111, respectively. Seventy-seven point eight percent (14/18) of patients with pancreatic cancer and none of the patients with chronic pancreatitis showed telomerase activity in cells collected from pancreatic duct brushings when cutoff value of telomerase activity was set at 2.0. The K-ras gene mutation rate (72.2%) in pancreatic cancer was higher than that in chronic pancreatitis (33.3%) (P<0.05). In considering of both telomerase activities and K-ras point mutation, the total positive rate was 83.3%(15/18), and the specificity was 100%.
Changes of telomerase activities and K-ras point mutation at codon 12 may be an early event of malignant progression in pancreatic cancer. Detection of telomerase activity and K-ras point mutation at codon 12 may be complementary to each other, and is useful in diagnosis of pancreatic cancer.
研究在内镜逆行胰胆管造影术(ERCP)期间从胰管刷检获取的脱落细胞中监测第12密码子K-ras点突变和端粒酶活性在胰腺癌诊断中的价值。
对27例患者ERCP期间从胰管刷检获取的脱落细胞进行检查,其中23例为胰腺癌患者,4例为慢性胰腺炎患者。采用聚合酶链反应和限制性片段长度多态性(PCR-RFLP)检测K-ras点突变。通过PCR和端粒重复序列扩增协议分析(PCR-TRAP-ELISA)检测端粒酶活性。
在从胰管刷检获取的21份脱落细胞样本中检测了27例患者的端粒酶活性。胰腺癌和慢性胰腺炎中端粒酶活性的D450值分别为0.446±0.27和0.041±0.0111。当端粒酶活性的临界值设定为2.0时,胰腺癌患者中有77.8%(14/18)在从胰管刷检收集的细胞中显示端粒酶活性,而慢性胰腺炎患者均未显示。胰腺癌的K-ras基因突变率(72.2%)高于慢性胰腺炎(33.3%)(P<0.05)。综合考虑端粒酶活性和K-ras点突变,总阳性率为83.3%(15/18),特异性为100%。
端粒酶活性变化和第12密码子K-ras点突变可能是胰腺癌恶性进展的早期事件。检测端粒酶活性和第12密码子K-ras点突变可能相互补充,对胰腺癌的诊断有帮助。